The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
Publication|Articles|September 21, 2023
- September 2023
- Volume 89
- Issue 9
Pharmacists Pet Peeves: September 2023
Advertisement
Freezing Frustrations
Curbside pickup, especially when it’s raining or snowing.
Articles in this issue
about 3 years ago
Interactive Case Studies: September 2023about 3 years ago
Tenth Circuit Decision Invalidates Oklahoma PBM Rulesabout 3 years ago
It’s Time to Gear Up for Fall Vaccinesabout 3 years ago
Menopause Condition Watchabout 3 years ago
Case Studies: Influenzaabout 3 years ago
Raising Awareness About Suicidality, Self-Harm in Adolescentsabout 3 years ago
Generic Product News - September 2023about 3 years ago
September 2023: RX Product Newsabout 3 years ago
Preserving Patient Access to Compounded Medications Act of 2017Advertisement
Related to this article
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Amivantamab Becomes First FDA-Approved Therapy in 10 Years for Pretreated Recurrent or Metastatic HNSCC
2
Understanding Kratom: Pharmacology, Safety, and Regulation
3
CVS Health to Split Into 2 Public Companies, Separating Retail and Specialty Pharmacy
4
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
5